Immix Biopharma Inc (IMMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immix Biopharma Inc (IMMX) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.83 Million) by net assets ($84.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immix Biopharma Inc net asset quality index to measure how much of total assets are equity-financed.
Immix Biopharma Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Immix Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IMMX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Immix Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immix Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangxi Chen Guang New Materials Co Ltd
SHG:605399
|
-0.014x |
|
Ram Ratna Wires Limited
NSE:RAMRAT
|
0.019x |
|
Fireweed Zinc Ltd
V:FWZ
|
-0.677x |
|
Zhejiang Sunrise Garment Group Co Ltd
SHG:605138
|
N/A |
|
Daewoong
KO:003090
|
0.052x |
|
QUADIENT SA ADR1/15/EO 1
F:NEQ0
|
N/A |
|
Dareway Software Co Ltd
SHG:688579
|
0.006x |
|
Deutsche Pfandbriefbank AG
XETRA:PBB
|
0.009x |
Annual Cash Flow Conversion Efficiency for Immix Biopharma Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Immix Biopharma Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Immix Biopharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.80 Million | $-23.93 Million | -0.255x | +76.84% |
| 2024-12-31 | $13.25 Million | $-14.60 Million | -1.101x | -56.94% |
| 2023-12-31 | $16.20 Million | $-11.37 Million | -0.702x | -24.66% |
| 2022-12-31 | $13.16 Million | $-7.41 Million | -0.563x | -537.23% |
| 2021-12-31 | $17.99 Million | $-1.59 Million | -0.088x | -203.27% |
| 2020-12-31 | $-4.73 Million | $-404.69K | 0.086x | -60.52% |
| 2019-12-31 | $-3.65 Million | $-790.03K | 0.217x | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.